News

Basel, Switzerland, January 5, 2012 - Basilea Pharmaceutica Ltd. (SIX:BSLN) today announced that it will apply in the second half of 2012 for approval of its antibiotic ceftobiprole in Europe. In addition, reporting of topline data for the alitretinoin U.S. phase III study for chronic refractory hand eczema will occur in the first quarter of this year. Basilea thus has the potential for two regulatory submissions in 2012.

Basel, Switzerland, December 7, 2011 - Basilea Pharmaceutica Ltd. (SIX:BSLN) today announced that Joachim Blatter has been appointed Chief Financial Officer (CFO) of Basilea Pharmaceutica International Ltd.

Basel, Switzerland, November 29, 2011 - Basilea Pharmaceutica Ltd. (SIX:BSLN) shareholders elect additional members to the board of directors.

Basel, Switzerland, October 28, 2011 - Basilea Pharmaceutica Ltd. (SIX:BSLN) announced today that its board of directors has set November 29, 2011 as date for the extraordinary general meeting of shareholders.

Basel, Switzerland, October 25, 2011 - Basilea Pharmaceutica Ltd. (SIX:BSLN) announced today that it has concluded the second phase I study with its novel sulfactam antibiotic BAL30072 for the potential treatment of life-threatening multidrug-resistant Gram-negative infections.

Basel, Switzerland, October 6, 2011 - Basilea Pharmaceutica Ltd. (SIX:BSLN) announced today that it has received a request to hold an extraordinary shareholders meeting.

Basel, Switzerland, October 3, 2011 - Basilea Pharmaceutica Ltd. (SIX:BSLN) announced today that Ronald Scott has been appointed Chief Operating Officer (COO) of Basilea Pharmaceutica International Ltd.

Basel, Switzerland, September 19, 2011 - Detailed results from the successful first phase I study with Basilea's novel antibiotic BAL30072 were presented at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Chicago, USA. Additional preclinical data underline the strong bactericidal activity and broad coverage of BAL30072 against clinically-relevant multidrug-resistant Gram-negative bacteria. Also, further data on Basilea's anti-MRSA broad-spectrum antibiotic ceftobiprole are presented.

Basel, Switzerland, September 7, 2011 - Basilea Pharmaceutica Ltd. (SIX:BSLN) announced today the initiation of the second phase I study with its novel sulfactam antibiotic BAL30072.

Basel, Switzerland, August 18, 2011 - Basilea Pharmaceutica Ltd. (SIX:BSLN) announced today its financial results for the first half-year 2011, reporting improved operating results, a solid cash position, 24% Toctino® sales growth in local currencies and the broadening of its clinical pipeline.